Non-small-cell lung cancer is the leading cause of cancer death for men and women in the ind ald nations. Identification of regions for genes involved in its pathogenesis has been difficult. Data presented here show three distinct regions identified on chromosome 11p. Two regions on 11pl3 distal to the Wilms tumor gene WT1 and on 11pl1.5 between the markers HBB and DIIS860 are described. The third region on the telomere of 11plS.5 has been previously described and is further delineated in this communication. By high-resolution mapping the size of each of these regions was estimated to be 2-3 megabases. The frequency of somatic loss of genetic information in these regions (57%, 71%, and 45%, respectively) was comparable to that seen in heritable tumors such as Wilms tumor (55%) and retinoblastoma (70%) and suggests their involvement in pathogenesis of non-small-cell lung cancer. Gene dosage analyses revealed duplication of the remaining allele in the majority of cases in the 11pl3 and the proximal 11p15.5 region but rarely in the distal 11pl5.5 region. In tumors with loss of heterozygosity in all three regions any combination of duplctin or simple deletion was observed, suggesting that loss ofheterozygosity occurs independently and perhaps at different points in time. These results provide a basis for studies directed at cloning potential tumor-suppressor genes in these regions and for assessing their biological and clinical sgnifcance In non-small-cell lung cancer.
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Non-small-cell lung cancer (NSCLC) comprises all primary malignant lung tumors except small-cell tumors and accounts for 80%o of all lung cancers. Many reasons should place NSCLC in the front line ofcancer research. Some ofthese are as follows: (i) the annual incidence of lung cancer is --3 x 106 worldwide and continues to rise; (ii) the number of young individuals without exposure to tobacco, in particular women, is rising; (iii) 87% of patients with NSCLC will die of the disease, and approximately 115,000 people annually succumb to NSCLC in the United States; (iv) the 5-year survival rate of 13% has not changed appreciably in the last 20 years; (v) screening of high-risk individuals with frequent chest radiographs and sputum cytological examinations was proven unsuccessful; and (vi) fresh specimens and wellcharacterized immortalized cell lines are now available (1) . The molecular genetic data presented here will provide a focus for investigations to isolate genetic elements involved in NSCLC development and progression.
The identification of regions for genes involved in the pathogenesis of NSCLC has been difficult because a possible familial rsk is obscured by environmental risk factors (2, 3) and because cytogenetic analyses have shown complex aberrations (4, 5) . Molecular genetic studies have implicated chromosomes 3 (6, 7), 5 (8), 8 (9), 9 (10, 11), 11 (12, 13) , and 17 (12) as possibly carrying disease-related regions. The present study was performed to specifically address whether chromosome 11 harbors NSCLC regions.
Mechanisms by which regions carrying recessive genetic information become unmasked are nondisjunction, mitotic recombination, deletion, and gene conversion (14) , which result in homozygosity in tumor cells. The size of such regions may be small and elude cytogenetic detection, as described for the childhood tumor rhabdomyosarcoma (15) , or large and visible by cytogenetic studies, as exemplified by small-cell lung cancer (6, 16) .
We have used 24 highly polymorphic markers on chromosome 11 with particular focus on bands 11p13 and 11p15.5 and assessed the frequency of loss of heterozygosity (LOH) in 28 pairs of normal and malignant tissue from patients with NSCLC and in 1 pair from a patient with small-cell lung cancer. In this communication, we show that three distinct regions on bands 11p13 and llpl5.5, two of which have not been previously described, are frequently deleted and may therefore identify loci for hitherto unknown tumor-suppressor genes.
MATERIALS AND METHODS
Tissue specimens obtained during surgery were immediately frozen in liquid nitrogen and stored at -1350C or -196%C until use. High molecular weight genomic DNA was extracted by a modified version of the method of Blin and Stafford (17 tTo whom reprint requests should be addressed.
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Genetics: Bepler and Garcia-Blanco hybridized at 650C for 12 hr in 3 x standard saline citrate (SSC)/1 mM EDTA/0.1% SDS/lOx Denhardt's solution/ 7% dextran sulfate containing salmon testis DNA (0.1 mg/ml) and random-primer-labeled (19) probes (1-5 x 106 cpm/ml), washed several times at variable stringencies to obtain the best results (0.05-0.5 x SSC/0.1% SDS/1 mM EDTA, 58-720C), and exposed to x-ray film with an intensifier screen at -80oC for hr.
Probes used (20) were pbc-Nl [American Type Culture Collection (ATCC)J, which detects an Msp I polymorphism at the HRAS locus; phins311 (ATCC), which detects a BamHI polymorphism at the IGF2 locus; phins310 (ATCC), which detects a Pst I polymorphism at the INS locus; pADJ762 (ATCC), which detects an Msp I polymorphism at the DIIS12 locus; p1596 (provided by Jack Lichy, National Cancer Institute, Bethesda, MD) (21) Three distinct regions showed frequent LOH, one on band 11p13 and two on band llplS.5 (Figs. 1-3) . The marker DIS16 on band 11p13 had LOH in 53% (10/19) of cases with heterozygosity in the normal lung specimen (Figs. 2 and 3) . DIS323, located centromeric to DIIS16, showed LOH in 2 of7 cases, which were both homozygous for DiIS16 and thus uninformative. This suggests that loss of somatic genetic information at this locus occurs in at least 57% of NSCLC. WTI, located between the markers DIIS325 and DIIS323 (29), had no LOH, which suggests that another tumorsuppressor gene is located on band 13 between DIIS323 and DIIS151, an area of =2.5 megabases (Mb) (29) .
DIS12 on band 15.5 had LOH in 71% (12/17) of cases.
HBB and D1IS860, the closest markers tested, were not deleted and therefore define the borders of this second NSCLC region (Figs. 1-3 7 of these 9 also had LOH at the INS locus, and 8 of these were heterozygous for HBB. Both groups of authors concluded that LOH for HRAS is a common finding in primary NSCLC and that the spectrum of LOH is similar in the different NSCLC subtypes. These reports favor a telomeric (INS-pter) location of a NSCLC tumor-suppressor gene, with LOH being observed in 23-43% of cases, and a possible second location for a tumor-suppressor gene between 11q13 and 11p13, albeit with low-frequency LOH (2325%). We studied three markers within or adjacent to the latter region (CAT, D1IS149, and TYR) and found LOH in only one tumor (D188/89; see Fig. 2), which accounts for 5-10%o of informative specimens. This low number suggests that this region is not of general importance for NSCLC pathogenesis. The differences in LOH frequencies among these studies are most likely caused by contamination of tumor specimens with normal diploid cells, resulting in a falsely positive heterozygosity of the tumor. Our data concur with the authors of refs. 12 and 13 in the location of a tumor-suppressor gene in the vicinity of the HRAS marker (LOH was found in 45% of tumors). However the extent of this region (Fig. 4, HRAS locus) was unclear, and the current work shows it not to extend beyond IGF2 and DRD4. Although DRD4 has been mapped telomeric to HRAS by genetic linkage analysis (39) , its exact physical location is unknown and may perhaps be centromeric to HRAS. Thus it remains unclear whether this LOH region includes the entire telomere. The same region has also been implicated in the pathogenesis of breast cancer (31) , rhabdomyosarcoma (15), Wilms tumor (35, 36) , bladder cancer (37) , and testicular cancer (38) . These data are schematically summarized in Fig. 
4.
We have found two NSCLC regions, one identified by D11S16 on band llpi3 (Fig. 4, DJJS16 ) and the other identified by DJJS12 on band llpl5.5 (Fig. 4, DJJS12) . The first region, on band llpl3, has not been previously de- scribed and is clearly distal to the WTI gene (29, 40) and outside ofthe region described by Weston et al. (12) . This and the frequency of LOH (57%), which is comparable to the one in Wilms tumor on band llpl3 (41), strongly suggest the presence of a tumor-suppressor gene within this region. Radice et aL (38) have described LOH in 4 of 12 testicular cancers (Fig. 4) . Because many of the markers used by those authors were uninformative, the minimal region of LOH could not be determined but extended from the telomere (HRAS locus) to perhaps as far as band llql3 (INT2 locus).
The second region, identified by the DJ1S12 locus, is of particular interest because of its high frequency (71%) of LOH, which is comparable to that found in retinoblastoma (14) . Ali polymorphic markers evaluated adjacent to this locus did not reveal LOH, which suggests that the area of interest is -2 Mb in size. Interestingly, data by Reeve et al. (35) and Wadey et a!. (36) suggest the presence of a second Wilms tumor locus (W12) in this region (Fig. 4) . The recent description of loss of genetic imprinting for IGF2 in Wilms tumor (42, 43) , however, suggests that loss of genetic control elements adjacent to the IGF2/HI9 genes could be the important event within this Wilms tumor LOH domain. There also appears to be some overlap of the second NSCLC region regions (31) (32) (33) (34) ; U, rhabdomyosarcoma regions (15, 30) ; C, Wilms tumor 2 regions (35, 36) ; A, bladder cancer region (37) ; Es, testicular cancer region (38) .
with known areas of frequent LOH in breast cancer (32) (33) (34) and rhabdomyosarcoma (15) (Fig. 4) . In addition, the centromeric part of this region overlaps with a chromosomal fragment which was recently shown to encode a tumorsuppressor activity when transferred to a rhabdomyosarcoma cell line (30) (Fig. 4) .
Several mechanisms leading to loss of genetic information in two or more noncontiguous regions in NSCLC are possible. Our gene dosage studies make it unlikely that the LOH events would have occurred concurrently through a complex rearrangement of a single chromosome, since LOH at different loci in the same tumor resulted from any combination of deletion and duplication, suggesting that LOH at various loci occurs independently and perhaps at different points in time. This can be addressed by studies assessing the pattern of LOH in premaliant bronchoepithelial tissue compared with carcinoma in situ and invasive cancer. Whether LOH at different loci within one tumor occurs on the same chromosome lip cannot be determined from our studies. Studies addressing the parental origin of the remaining alleles could help answer this question. Previous studies have demonstrated a paternal origin of the remaining alleles in rhabdomyosarcoma (44) and Wilms tumor (45) , which suggests that LOH occurs on the same chromosome lip.
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The data presented provide a focus for investigations to identify and characterize tumor-suppressor genes on chromosome lip involved in NSCLC development and progression. 
